CJC-1295: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:CJC-1295}} | |||
==Overview== | == Overview == | ||
CJC-1295 | [[File:CJC-1295_DAC.svg|thumb|right|Chemical structure of CJC-1295 with DAC]] | ||
'''CJC-1295''' is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog. It is primarily used in research settings to study its effects on growth hormone (GH) secretion and its potential therapeutic applications. | |||
==Mechanism of Action== | == Mechanism of Action == | ||
CJC-1295 works by binding to the [[growth hormone-releasing hormone receptor]] (GHRHR) on the surface of [[pituitary gland]] cells. This binding stimulates the release of [[growth hormone]] from the pituitary gland into the bloodstream. The increased levels of growth hormone can lead to various physiological effects, including increased muscle mass, reduced body fat, and improved recovery from injuries. | |||
== | == Structure and Composition == | ||
CJC-1295 has been | CJC-1295 is a modified form of the natural GHRH. It has been engineered to have a longer half-life than endogenous GHRH, allowing for less frequent dosing. The addition of a Drug Affinity Complex (DAC) extends its half-life by allowing it to bind to [[albumin]] in the bloodstream, thereby protecting it from rapid degradation. | ||
== Clinical Applications == | |||
While CJC-1295 is not approved for clinical use, it is of interest in the field of [[endocrinology]] for its potential to treat conditions associated with growth hormone deficiency. Research is ongoing to determine its efficacy and safety in various populations, including those with [[HIV/AIDS]]-related wasting and age-related muscle loss. | |||
== Side Effects == | |||
Potential side effects of CJC-1295 include injection site reactions, such as redness and swelling, as well as systemic effects like headache, nausea, and dizziness. Long-term effects are not well-documented due to the lack of extensive clinical trials. | |||
== | == Related Compounds == | ||
CJC-1295 is often compared to other GHRH analogs and [[growth hormone secretagogues]] such as [[Sermorelin]] and [[Ipamorelin]]. These compounds also aim to increase growth hormone levels but differ in their structure, half-life, and receptor affinity. | |||
== | == Research and Development == | ||
Research on CJC-1295 is ongoing, with studies focusing on its pharmacokinetics, optimal dosing regimens, and potential therapeutic applications. Animal studies have shown promising results, but more human trials are needed to fully understand its benefits and risks. | |||
== | == Related Pages == | ||
* [[Growth hormone-releasing hormone]] | |||
* [[Growth hormone]] | |||
* [[Pituitary gland]] | |||
* [[Endocrinology]] | |||
[[Category:Peptides]] | [[Category:Peptides]] | ||
[[Category: | [[Category:Growth hormone secretagogues]] | ||
Latest revision as of 03:42, 13 February 2025
Overview[edit]

CJC-1295 is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog. It is primarily used in research settings to study its effects on growth hormone (GH) secretion and its potential therapeutic applications.
Mechanism of Action[edit]
CJC-1295 works by binding to the growth hormone-releasing hormone receptor (GHRHR) on the surface of pituitary gland cells. This binding stimulates the release of growth hormone from the pituitary gland into the bloodstream. The increased levels of growth hormone can lead to various physiological effects, including increased muscle mass, reduced body fat, and improved recovery from injuries.
Structure and Composition[edit]
CJC-1295 is a modified form of the natural GHRH. It has been engineered to have a longer half-life than endogenous GHRH, allowing for less frequent dosing. The addition of a Drug Affinity Complex (DAC) extends its half-life by allowing it to bind to albumin in the bloodstream, thereby protecting it from rapid degradation.
Clinical Applications[edit]
While CJC-1295 is not approved for clinical use, it is of interest in the field of endocrinology for its potential to treat conditions associated with growth hormone deficiency. Research is ongoing to determine its efficacy and safety in various populations, including those with HIV/AIDS-related wasting and age-related muscle loss.
Side Effects[edit]
Potential side effects of CJC-1295 include injection site reactions, such as redness and swelling, as well as systemic effects like headache, nausea, and dizziness. Long-term effects are not well-documented due to the lack of extensive clinical trials.
Related Compounds[edit]
CJC-1295 is often compared to other GHRH analogs and growth hormone secretagogues such as Sermorelin and Ipamorelin. These compounds also aim to increase growth hormone levels but differ in their structure, half-life, and receptor affinity.
Research and Development[edit]
Research on CJC-1295 is ongoing, with studies focusing on its pharmacokinetics, optimal dosing regimens, and potential therapeutic applications. Animal studies have shown promising results, but more human trials are needed to fully understand its benefits and risks.